- Home
- DMC vs VOR Comparison
DMC vs VOR Comparison
Compare DMC & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | DMC | VOR |
|---|---|---|
| Founded | N/A | 2015 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 1999 | 2021 |
Fundamental Metrics
Financial Performance| Metric | DMC | VOR |
|---|---|---|
| Price | $31.39 | $23.53 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $45.33 |
| AVG Volume (30 Days) | 337.5K | ★ 766.8K |
| Earning Date | N/A | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $4,322,300,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $48.52 | ★ N/A |
| Revenue Growth | ★ 0.98 | N/A |
| 52 Week Low | $27.51 | $1.90 |
| 52 Week High | $32.50 | $49.95 |
Technical Indicators
Market Signals| Indicator | DMC | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 66.18 | 62.24 |
| Support Level | $27.82 | $21.75 |
| Resistance Level | $32.50 | $24.44 |
| Average True Range (ATR) | 0.73 | 1.07 |
| MACD | 0.07 | -0.12 |
| Stochastic Oscillator | 69.42 | 78.49 |
Price Performance
Historical ComparisonAbout DMC Del Monte Corporation Ordinary Shares
Del Monte Corp is a producer, marketer, and distributor of fresh, packaged, value-added, and canned food products. Its products are sold in multiple countries and are marketed under the DEL MONTE brand and other brands.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.